Emerging treatments for the prevention of type 1 diabetes

Bibliography

• Prevalence of Diabetes in the United States based on US Population: 275 million in 2000. Lancet 2000;355:873-6. Available from: http://www.cdc.gov/diabetes/pubs/estimates.htm; Harris MI. In: National Diabetes Data Group. Diabetes in America. 2nd edition. Bethesda, Md: NIDDK; 1995:15-36; U.S. Census Bureau Statistical Abstract of the U.S.; 2001
   Google Scholar
• Norris JM, Dorman JS, Rewers M, The epidemiology and genetics of insulin-dependent diabetes mellitus. Arch Pathol Lab Med 1987;111:905-9
   PubMed Web of Science ®Google Scholar
• Dahlquist G. The etiology of type 1 diabetes: an epidemiological perspective. Acta Paediatr Suppl 1998;425:5-10
   PubMedGoogle Scholar
• Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report Of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2002;25:S5-20
   Google Scholar
• Winter WE, Maclaren NK. Autoimmune endocrinopathies. In: Stiehm ER, editor, Immunologic disorders in infants and children. 4th edition. WB Saunders, Philadelphia (PA); 1996. p. 824-54
   Google Scholar
• Kukreja A, Maclaren NK. Autoimmunity and diabetes. J Clin Endocrinol Metab 1999;84(12):4371-8
   PubMed Web of Science ®Google Scholar
• Kawasaki E, Gill RG, Eisenbarth GS. Type 1 diabetes mellitus. In: Eisenbarth GS, editor, Endocrine and organ specific autoimmunity. RG Landes, Austin (TX); 1999. p. 149-82
   Google Scholar
• Eisenbarth GS. Update in type 1 diabetes. J Clin Endocrinol Metab 2007; 92(7):2403-7
   PubMed Web of Science ®Google Scholar
• Steck AK, Zhang W, Bugawan TL, Do non-HLA genes influence development of persistent islet autoimmunity and type 1 diabetes in children with high-risk HLA-DR, DQ genotypes? Diabetes 2009;58(4):1028-33
   PubMed Web of Science ®Google Scholar
• Barnett AH, Eff C, Leslie RD, Pyke DA. Diabetes in identical twins. A study of 200 pairs. Diabetologia 1981;20(2):87-93
   PubMed Web of Science ®Google Scholar
• Akerblom HK, Knip M. Putative environmental factors in type 1 diabetes. Diabetes Metab Rev 1998;14(1):31-67
   PubMed Web of Science ®Google Scholar
• Eisenbarth GS. Type I diabetes mellitus: a chronic autoimmune disease. N Engl J Med 1986;314:1360-8
   PubMed Web of Science ®Google Scholar
• Barker JM, Barriga KJ, Yu L, Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 2004;89(8):3896-902
   PubMed Web of Science ®Google Scholar
• Atkinson MA. ADA Outstanding Scientific Achievement Lecture 2004. Thirty years of investigating the autoimmune basis for type 1 diabetes: why can't we prevent or reverse this disease? Diabetes 2005;54(5):1253-63
   PubMed Web of Science ®Google Scholar
• Atkinson M, Gale EA. Infant diets and type 1 diabetes: too early, too late, or just too complicated? JAMA 2003;290:1771-2
   PubMed Web of Science ®Google Scholar
• Abiru N, Yu L, Redondo M, Eisenbarth GS. Modification of the environment is not the most efficient way to prevent type 1 diabetes. Diabetes Technolv Ther 2000;2:609-16
   PubMedGoogle Scholar
• Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221-9
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977-86
   PubMed Web of Science ®Google Scholar
• Guz Y, Nasir I, Teitelman G. Regeneration of pancreatic beta-cells from intra-islet precursor cells in an experimental model of diabetes. Endocrinology 2001;142:4956-68
   PubMed Web of Science ®Google Scholar
• Garcia-Ocana A, Vasavada RC, Cebrian A, Transgenic overexpression of hepatocyte growth factor in the beta−cell markedly improves islet function and islet transplant outcomes in mice. Diabetes 2001;50:2752-62
   PubMed Web of Science ®Google Scholar
• American D Association. Standards of medical care in diabetes–2009. Diabetes Care 2009;32(Suppl 1):S13-61
   PubMed Web of Science ®Google Scholar
• Soedamah-Muthu SS, Fuller JH, Mulnier HE, High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care 2006;29(4):798-804
   PubMed Web of Science ®Google Scholar
• The DCCT Research Group. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 1995;18(11):1415-27
   PubMed Web of Science ®Google Scholar
• Purnell JQ, Hokanson JE, Marcovina SM, Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998;280(2):140-6
   Google Scholar
• Guz Y, Nasir I, Teitelman G. Regeneration of pancreatic beta−cells from intra-islet precursor cells in an experimental model of diabetes. Endocrinology 2001;142;4956-68
   PubMed Web of Science ®Google Scholar
• Garcia-Ocana A, Vasavada RC, Cebrian A, Transgenic overexpression of hepatocyte growth factor in the beta-cell markedly improves islet function and islet transplant outcomes in mice. Diabetes 2001;50:2752-62
   PubMed Web of Science ®Google Scholar
• Kawasaki E, Gill RG, Eisenbarth GS. Type 1 diabetes. In: Eisenbarth GS, editor, Endocrine and organ specific autoimmunity. R.G. Landes Co., Austin, TX; 1999:149-82
   Google Scholar
• Jansen A, Homo-Delarche F, Hooijkaas H, Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and beta−cell destruction in NOD mice. Diabetes 1994;43:667-75
   PubMed Web of Science ®Google Scholar
• Kawasaki E, Abiru N, Eguchi K. Prevention of type 1 diabetes: from the view point of beta-cell damage. Diabetes Res Clin Pract 2004;66:S27-32
   PubMed Web of Science ®Google Scholar
• Suarez-Pinzon WL, Rabinovitch A. Approaches to type 1 diabetes prevention by intervention in cytokine immunoregulatory circuits. Int J Exp Diab Res 2001;2:3-17
   Google Scholar
• Chang TW, Kung PC, Gingras SP, Goldstein G. Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T-cells? Proc Natl Acad Sci USA 1981;78(3):1805-8
   PubMed Web of Science ®Google Scholar
• Reinherz EL, Meuer S, Fitzgerald KA, Antigen recognition by human T lymphocytes is linked to surface expression of the T3 molecular complex. Cell 1982;30(3):735-43
   PubMed Web of Science ®Google Scholar
• Van den Elsen P, Shepley BA, Borst J, Isolation of cDNA clones encoding the 20K T3 glycoprotein of human T-cell receptor complex. Nature 1984;312(5993):413-18
   PubMed Web of Science ®Google Scholar
• Miller RA, Maloney DG, McKillop J, Levy R. In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood 1981;58(1):78-86
   PubMed Web of Science ®Google Scholar
• Herold KC, Bluestone JA, Montag AG, Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 1992;41(3):385-91
   PubMed Web of Science ®Google Scholar
• Couzin J. Clinical trials. Diabetes' brave new world. Science 2003;300(5627):1862-5
   PubMed Web of Science ®Google Scholar
• Baeder WL, Sredy J, Sehgal SN, Rapamycin prevents the onset of insulin dependent diabetes mellitus (IDDM) in NOD mice. Clin Exp Immunol 1992;89(2):174-8
   PubMed Web of Science ®Google Scholar
• Rabinovitch A, Suarez-Pinzon WL, Shapiro AM, Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 2002;51(3):638-45
   PubMed Web of Science ®Google Scholar
• Kolb H, Burkart V. Nicotinamide in type 1 diabetes. Mechanism of action revisited. Diabetes Care 1999;22(Suppl 2):B16-20
   PubMed Web of Science ®Google Scholar
• Gale EA. Theory and practice of nicotinamide trials in pre-type 1 diabetes. J Pediatr Endocrinol Metab 1996;9(3);375-9
   PubMed Web of Science ®Google Scholar
• Knip M. Prediction and prevention of type 1 diabetes. Acta Paediatr Suppl 1998;425(Suppl):54-62
   PubMedGoogle Scholar
• Elliott RB, Pilcher CC, Stewart A, A universal model of antibody prediction (MAP) of type 1 diabetes in children. Ann NY Acad Sci 1993;696:333-41
   PubMed Web of Science ®Google Scholar
• Lazarow A. Protection against alloxan diabetes. Anat Rec 1947;97:353-8
   PubMedGoogle Scholar
• Gale EA. European Nicotinamide Diabetes Intervention Trial Group. Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetologia 2003;46(3):339-46
   PubMed Web of Science ®Google Scholar
• Pozzilli P. Prevention of insulin-dependent diabetes mellitus. Diabetes Metab Rev 1998;14(1):69-84
   PubMed Web of Science ®Google Scholar
• European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004;363(9413):925-31
   PubMed Web of Science ®Google Scholar
• Norris J, Pietropaolo M. A bovine albumin peptide as a possible trigger of insulin-dependent diabetes mellitus. J Endocrinol Invest 1994;17(7):565-72
   PubMed Web of Science ®Google Scholar
• Karlsson MG, Ludvigsson J. The ABBOS-peptide from bovine serum albumin causes an IFN-gamma and IL-4 mRNA response in lymphocytes from children with recent onset of type 1 diabetes. Diabetes Res Clin Pract 2000;47(3):199-207
   PubMed Web of Science ®Google Scholar
• Hanninen A. Prevention of autoimmune type 1 diabetes via mucosal tolerance: is mucosal autoantigen administration as safe and effective as it should be? Scand J Immunol 2000;52(3):217-25
   PubMed Web of Science ®Google Scholar
• Jun HS, Khil LY, Yoon JW. Role of glutamic acid decarboxylase in the pathogenesis of type 1 diabetes. Cell Mol Life Sci 2002;59(11):1892-901
   PubMed Web of Science ®Google Scholar
• Tisch R, Yang XD, Singer SM, Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993;366(6450):72-5
   PubMed Web of Science ®Google Scholar
• Kaufman DL, Clare-Salzler M, Tian J, Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993;366(6450):69-72
   PubMed Web of Science ®Google Scholar
• Ludvigsson J, Faresjo M, Hjorth M, GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359:1909-20
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Rituximab, B-Lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-52
   PubMed Web of Science ®Google Scholar
• Parving HH, Tarnow L, Nielsen FS, Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. Diabetes Care 1998;22(3):478-83
   Web of Science ®Google Scholar
• Elias D, Meilin A, Ablamunits V, Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and down regulates autoimmunity to various beta−cell antigens. Diabetes 1997;46(5):758-64
   PubMed Web of Science ®Google Scholar
• Herold KC, Hagopian W, Auger JA, Anti-CD3 monoclonal antibody in newonset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-8
   PubMed Web of Science ®Google Scholar
• Herold KC, Gitelman SE, Masharani U, A single course of anti-CD3 monoclonal antibody hOKT31(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-9
   PubMed Web of Science ®Google Scholar
• Keymeulen B, Vandemeulebroucke E, Ziegler AG, Insulin needs after CD3- antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-608
   PubMed Web of Science ®Google Scholar
• Eisenbarth GS, editor. Type 1A diabetes:cellular, molecular and clinical immunology. Teaching slides, Available from: www.barbaradaviscenter.org
   Google Scholar